Myonexus Therapeutics
A Clinical Stage Limb-Girdle Muscular Dystrophy Gene Therapy Company.
Launch date
Market cap
-
Enterprise valuation
€150m (Public information from Feb 2019)
New Albany Ohio (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$2.5m | Seed | ||
$60.0m | Late VC | ||
$165m Valuation: $165m | Acquisition | ||
| Total Funding | €56.8m | ||
Recent News about Myonexus Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.